research use only
Cat.No.S2043
|
In vitro |
DMSO
: 43 mg/mL
(199.29 mM)
Water : 43 mg/mL Ethanol : 43 mg/mL |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 215.76 | Formula | C12H21N.HCl |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 41100-52-1 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | N/A | SMILES | CC12CC3CC(C1)(CC(C3)(C2)N)C.Cl | ||
Read more about storage stability stock solution CAS number SMILES
| Targets/IC50/Ki |
NMDAR
CYP2B6
(Cell-free assay) 0.51 μM(Ki)
CYP2B6
(Cell-free assay) 1.12 μM
CYP2D6
(Cell-free assay) 84.4 μM(Ki)
CYP2D6
(Cell-free assay) 242.4 μM
|
|---|---|
| In vitro |
Memantine inhibits CYP2B6 and CYP2D6 activities with Ki of 76.7 and 94.9 µM, respectively, in human liver microsomes. |
References |
|
(data from https://clinicaltrials.gov, updated on 2026-03-04)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT04302870 | RECRUITING | Motor Neuron Disease, Amyotrophic Lateral Sclerosis |
University of Edinburgh |
2020-02-27 | PHASE2; PHASE3 |
| NCT07560878 | RECRUITING | Major Depression |
Mclean Hospital |
2026-03-11 | EARLY_PHASE1 |
| NCT07470606 | NOT_YET_RECRUITING | Brain Tumor |
The University of Texas Health Science Center at San Antonio |
2026-03 | PHASE2 |
| NCT00262470 | ACTIVE_NOT_RECRUITING | Tachycardia; Chronic Orthostatic Intolerance |
Satish R. Raj |
1997-04 | PHASE1; PHASE2 |
| NCT06727773 | RECRUITING | Breast Cancer; Locally Advanced Breast Cancer; Cognitive Impairment; Cognitive Decline; Cognitive Change; Breast Cancer Stage I; Breast Cancer Stage II; Breast Cancer Stage III |
UNC Lineberger Comprehensive Cancer Center |
2025-08-19 | PHASE2 |
| NCT07505979 | NOT_YET_RECRUITING | Brain Metastases From Solid Tumors |
National Taiwan University Hospital |
2026-04 | PHASE2 |
Read more about Clinical Trials
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.